References
1. The Shield test meets performance requirements for Medicare coverage under NCD 210.3.
2. American Cancer Society. Key Statistics for Colorectal Cancer. Accessed online May 8, 2023.
https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html
3. American Cancer
Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024.
4. Doubeni, C, et al. Modifiable Failures in the Colorectal Cancer
Screening Process and Their Association with Risk of Death. Gastroenterology. 2019 Jan; 156(1): 6374.e6.
5. American Society of Clinical Oncology.
Colorectal Cancer: Statistics. https://www.cancer.net/cancer-types/colorectal-cancer/statistics#. Accessed April 23, 2024.
6. American Cancer
Society National Colorectal Cancer Roundtable. 80% in Every Community. https://nccrt.org/our-impact/80-in-every-community/.
Accessed February 15, 2024.
7. Rich T, Raymond V, Lang K. Where are we today? Efforts to understand strategies and barriers to physician issuance of
a recommendation for colorectal cancer screening: a systematic review. Gastroenterology. 2020;158(6 suppl 1):S-918. doi:10.1016/S0016-5085(20)32981-4.
8. Raymond V, Foster G, Hong Y et al. Implementation of Blood-Based Colorectal Cancer Screening: Real-World Clinical Experience. ACG 2023 Annual Scientific
Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.
9. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence
to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995.
10. Gellad ZF, Stechuchak KM, Fisher DA, et al.
Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol. 2011;106(6):1125-1134.
11. Inadomi
JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582.
12. Exact Sciences. Third quarter 2019 webcast and conference call. Updated October 29, 2019. Accessed December 17, 2021. https:/investor.exactsciences.com/investor-relations/events-and-presentations/event-details/2019/Third-Quarter-2019-Webcast-Conference-Call/default.aspx
13. Chung DC, Gray DM, Singh H et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med 2024;390:973-83.
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Mike Weist
press@guardanthealth.com
+1 317-371-0035